276 related articles for article (PubMed ID: 26422291)
61. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
Beca F; Krings G; Chen YY; Hosfield EM; Vohra P; Sibley RK; Troxell ML; West RB; Allison KH; Bean GR
Mod Pathol; 2020 Aug; 33(8):1518-1526. PubMed ID: 32123305
[TBL] [Abstract][Full Text] [Related]
62. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
63. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.
Fora AA; McMahon JA; Wilding G; Groman A; Ma WW; Romano KS; Fakih MG
Oncology; 2013; 84(4):210-3. PubMed ID: 23328486
[TBL] [Abstract][Full Text] [Related]
64. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
65. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
66. [A Case of Rectal Cancer Completely Resected after Successful Treatment with Irinotecan plus Cetuximab-Induced Interstitial Pneumonia with Steroid Pulse Therapy].
Miyake M; Takeda T; Haraguchi N; Uemura M; Ikeda M; Miyazaki M; Maeda S; Yamamoto K; Hama N; Nishikawa K; Miyamoto A; Hirao M; Nakamori S; Sekimoto M
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2334-6. PubMed ID: 26805355
[TBL] [Abstract][Full Text] [Related]
67. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.
Schønnemann KR; Yilmaz M; Bjerregaard JK; Nielsen KM; Pfeiffer P
Eur J Cancer; 2012 Mar; 48(4):510-7. PubMed ID: 22244801
[TBL] [Abstract][Full Text] [Related]
68. Cetuximab in metastatic colorectal cancer.
Broadbridge VT; Karapetis CS; Price TJ
Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
[TBL] [Abstract][Full Text] [Related]
69. Eruptive tufted angiomas in a patient with Crohn's disease.
Al-Za'abi AM; Ghazarian D; Greenberg GR; Shaw JC
J Clin Pathol; 2005 Feb; 58(2):214-6. PubMed ID: 15677546
[TBL] [Abstract][Full Text] [Related]
70. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Van Cutsem E; Tejpar S; Vanbeckevoort D; Peeters M; Humblet Y; Gelderblom H; Vermorken JB; Viret F; Glimelius B; Gallerani E; Hendlisz A; Cats A; Moehler M; Sagaert X; Vlassak S; Schlichting M; Ciardiello F
J Clin Oncol; 2012 Aug; 30(23):2861-8. PubMed ID: 22753904
[TBL] [Abstract][Full Text] [Related]
71. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
72. Endothelium capture-based liver segment imaging using vascular endothelial growth factor receptor 2 in preclinical ex vivo models.
Kyuno D; Qian B; Groß W; Schäfer M; Ryschich E
BJS Open; 2020 Apr; 4(2):332-341. PubMed ID: 31965760
[TBL] [Abstract][Full Text] [Related]
73. Transient vocal fold lesion and hoarseness associated with the use of ramucirumab: Case report.
Melo ÉGA; Silveira PAL; Mello CA
Eur Ann Otorhinolaryngol Head Neck Dis; 2019 Sep; 136(4):317-319. PubMed ID: 30876850
[TBL] [Abstract][Full Text] [Related]
74.
Graziano F; Fischer NW; Bagaloni I; Di Bartolomeo M; Lonardi S; Vincenzi B; Perrone G; Fornaro L; Ongaro E; Aprile G; Bisonni R; Prisciandaro M; Malkin D; Gariépy J; Fassan M; Loupakis F; Sarti D; Del Prete M; Catalano V; Alessandroni P; Magnani M; Ruzzo A
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722340
[TBL] [Abstract][Full Text] [Related]
75. Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment.
Ibe T; Hamamoto Y; Takabatake M; Kamoshida S
BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31776151
[TBL] [Abstract][Full Text] [Related]
76. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.
Lowery CD; Blosser W; Dowless M; Renschler M; Perez LV; Stephens J; Pytowski B; Wasserstrom H; Stancato LF; Falcon B
Oncotarget; 2019 Sep; 10(53):5523-5533. PubMed ID: 31565186
[TBL] [Abstract][Full Text] [Related]
77. Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review.
Fujii T; Kawasoe K; Tonooka A; Ohta A; Nitta K
Medicine (Baltimore); 2019 Jul; 98(27):e16236. PubMed ID: 31277139
[TBL] [Abstract][Full Text] [Related]
78. Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.
Zhrebker L; Cherni I; Gross LM; Hinshelwood MM; Reese M; Aldrich J; Guileyardo JM; Roberts WC; Craig D; Von Hoff DD; Mennel RG; Carpten JD
BMC Cancer; 2017 Jan; 17(1):17. PubMed ID: 28056866
[TBL] [Abstract][Full Text] [Related]
79. Clinical advances in the development of novel VEGFR2 inhibitors.
Fontanella C; Ongaro E; Bolzonello S; Guardascione M; Fasola G; Aprile G
Ann Transl Med; 2014 Dec; 2(12):123. PubMed ID: 25568876
[TBL] [Abstract][Full Text] [Related]
80. Ramucirumab-induced Multiple Haemangiomas of the Skin: Two Case Reports.
Kosumi H; Nishie W; Sugai T; Toyonaga E; Yoshimoto N; Nakamura H; Horibe R; Kitamura Y; Nakatsumi H; Shimizu H
Acta Derm Venereol; 2018 Apr; 98(4):454-455. PubMed ID: 29327066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
